Last updated: February 19, 2026
Iothalamate meglumine is a radiocontrast agent used in medical imaging. Its market is characterized by demand driven by diagnostic procedures, competition from alternative contrast agents, and patent expiry. The financial trajectory is influenced by manufacturing costs, regulatory approvals, and healthcare spending.
What is the Global Market Size and Projected Growth for Iothalamate Meglumine?
The global market for iothalamate meglumine is projected to reach approximately $150 million by 2028, with a compound annual growth rate (CAGR) of 3.5% from 2023 to 2028. This growth is primarily attributed to the increasing prevalence of diagnostic imaging procedures, particularly in cardiology and neurology. The aging global population is a significant driver, leading to a higher incidence of conditions requiring diagnostic imaging, such as cardiovascular diseases and neurological disorders [1].
Key Market Drivers
- Increasing Demand for Diagnostic Imaging: The rise in diagnostic imaging procedures is the primary growth factor. Procedures like computed tomography (CT) scans and digital subtraction angiography (DSA) commonly utilize iothalamate meglumine. Global CT scanner shipments are projected to increase, directly impacting contrast media demand [2].
- Growing Geriatric Population: As the proportion of individuals over 65 increases globally, so does the incidence of age-related conditions requiring detailed medical imaging. This demographic shift is expected to sustain demand for diagnostic agents [3].
- Technological Advancements in Imaging: While iothalamate meglumine is a mature product, advancements in imaging technology that enhance image clarity and reduce scan times can indirectly support its continued use by enabling more effective diagnosis.
- Emerging Market Penetration: Increased healthcare infrastructure development and rising disposable incomes in emerging economies are expanding access to advanced diagnostic imaging, creating new demand centers for iothalamate meglumine [4].
Market Restraints
- Competition from Alternative Contrast Agents: Iodine-based contrast agents, including iothalamate meglumine, face competition from non-iodine based agents such as gadolinium-based contrast agents used in MRI. Furthermore, newer generations of iodinated contrast media with improved safety profiles and efficacy can displace older agents.
- Side Effects and Adverse Reactions: Though generally well-tolerated, iothalamate meglumine can cause adverse reactions, including allergic-type reactions and nephrotoxicity, particularly in patients with pre-existing renal conditions. This necessitates careful patient selection and monitoring, and can lead to the preference for agents perceived as safer in certain patient populations [5].
- Patent Expiries and Generic Competition: The patent landscape for iothalamate meglumine has matured, leading to increased generic competition. This drives down prices and can reduce the revenue generated by branded manufacturers. The original patents for iothalamate meglumine have long expired.
- Manufacturing Costs and Regulatory Hurdles: The production of radiocontrast agents involves complex synthesis and strict quality control measures, contributing to manufacturing costs. Stringent regulatory approval processes in different regions add to the time and expense of bringing products to market [6].
What is the Competitive Landscape for Iothalamate Meglumine?
The competitive landscape for iothalamate meglumine is fragmented, with several established pharmaceutical companies and generic manufacturers producing and distributing the agent. Key players focus on manufacturing efficiency, supply chain reliability, and meeting regulatory standards.
Major Manufacturers and Suppliers
- Guerbet: A significant player in the contrast media market, Guerbet offers a range of iodinated contrast agents.
- GE Healthcare: A subsidiary of General Electric, GE Healthcare is a major supplier of medical imaging equipment and contrast media, including iothalamate meglumine.
- Bracco Imaging: Another prominent company in the diagnostic imaging sector, Bracco offers a portfolio of contrast agents.
- Various Generic Manufacturers: A substantial portion of the market share is held by generic manufacturers, particularly in regions with mature pharmaceutical markets. These companies often compete on price.
Product Segmentation
Iothalamate meglumine is primarily used in its injectable form for various imaging modalities:
- Computed Tomography (CT) Scans: Used to enhance visualization of organs, blood vessels, and tissues.
- Angiography (DSA): Used to visualize blood vessels to detect blockages or other abnormalities.
- Urography: Used to visualize the kidneys and urinary tract.
The market is further segmented by type of use:
- Hospital Use: The largest segment, driven by inpatient procedures.
- Diagnostic Imaging Centers: Growing segment due to outpatient diagnostic services.
What are the Key Patent and Regulatory Considerations for Iothalamate Meglumine?
The patent status of iothalamate meglumine is that its primary composition of matter patents have expired. This has opened the market to generic competition. Regulatory approval remains a critical factor for market access and continued sales.
Patent Expiry and Generic Entry
The original patents covering the composition of matter for iothalamate meglumine have expired. This means that new companies can manufacture and sell generic versions of the drug without infringing on core intellectual property rights. The timeline for patent expiry for many foundational contrast agents has passed decades ago.
Regulatory Approvals and Standards
Manufacturers must obtain approval from regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and equivalent agencies in other countries to market iothalamate meglumine. These approvals require demonstration of safety, efficacy, and consistent manufacturing quality.
- FDA Approval: Manufacturers must submit New Drug Applications (NDAs) or Abbreviated New Drug Applications (ANDAs) for generic versions. The FDA reviews manufacturing processes, quality control, and clinical data for equivalence to the reference product.
- EMA Approval: In Europe, marketing authorization is granted by the EMA or national competent authorities. Compliance with Good Manufacturing Practices (GMP) is essential.
- Pharmacopeial Standards: Iothalamate meglumine must meet the standards set by pharmacopeias such as the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.) for purity, potency, and other quality attributes.
Post-Market Surveillance and Pharmacovigilance
Even after approval, manufacturers are required to engage in post-market surveillance to monitor for any new safety concerns or adverse events. This pharmacovigilance is critical for maintaining regulatory compliance and ensuring patient safety.
What is the Financial Trajectory and Profitability of Iothalamate Meglumine?
The financial trajectory of iothalamate meglumine is characterized by declining profit margins due to generic competition, but stable revenue streams driven by consistent diagnostic demand. Manufacturing efficiency and cost management are crucial for profitability.
Pricing and Revenue Generation
Following patent expiry, the price of iothalamate meglumine has significantly decreased due to competition from generic manufacturers. While the volume of sales may remain steady or even increase with growing diagnostic demand, the revenue generated per unit has fallen. The market is highly price-sensitive.
Estimated Average Selling Price (ASP) Trends:
- Branded Product (Pre-Generic Entry): $50 - $100 per vial (highly variable by concentration and volume).
- Generic Product (Current): $10 - $30 per vial.
Revenue is primarily generated from sales to hospitals, clinics, and diagnostic imaging centers. The overall market revenue is projected to grow modestly due to volume increases outweighing price erosion.
Manufacturing Costs and Profit Margins
The manufacturing of iothalamate meglumine involves several stages, including chemical synthesis of the active pharmaceutical ingredient (API) and sterile formulation.
Key Cost Components:
- API Synthesis: Raw materials, chemical processing, and quality control.
- Formulation and Filling: Sterilization, dilution, and aseptic filling into vials or syringes.
- Packaging and Labeling: Compliance with regulatory requirements for labeling and secondary packaging.
- Quality Assurance and Control (QA/QC): Extensive testing at multiple stages.
- Regulatory Compliance: Costs associated with maintaining GMP standards and regulatory filings.
Profit margins for branded manufacturers have been significantly impacted. Generic manufacturers achieve profitability through economies of scale, streamlined production processes, and aggressive cost control. For generic players, profit margins might range from 15% to 30% on average, depending on market position and operational efficiency.
Investment and R&D Considerations
Given the mature nature of iothalamate meglumine and its patent expiry, significant investment in novel R&D for this specific compound is unlikely. Investment focus has shifted towards:
- Manufacturing Process Optimization: Improving efficiency and reducing costs for existing generic production.
- Supply Chain Security: Ensuring reliable sourcing of raw materials and consistent product availability.
- Development of Newer Contrast Agents: Companies are more likely to invest in the R&D of next-generation contrast agents with enhanced properties or different mechanisms of action.
Key Takeaways
Iothalamate meglumine maintains a stable demand driven by essential diagnostic imaging procedures, particularly CT scans and angiography. The market is mature, with primary composition of matter patents expired, leading to robust generic competition and pressure on pricing. Key manufacturers include Guerbet, GE Healthcare, and Bracco Imaging, alongside numerous generic producers. Profitability for generic manufacturers relies heavily on manufacturing efficiencies and economies of scale, as profit margins are compressed compared to the branded era. Regulatory compliance with bodies like the FDA and EMA is critical for market access and continued sales, with ongoing pharmacovigilance requirements. The financial trajectory is one of modest volume-driven revenue growth, counterbalanced by significant price erosion.
Frequently Asked Questions
1. What is the primary therapeutic use of iothalamate meglumine?
Iothalamate meglumine is a radiocontrast agent used in medical imaging to enhance the visibility of internal body structures, particularly blood vessels and organs, during X-ray-based examinations such as CT scans and angiography.
2. What are the main side effects associated with iothalamate meglumine?
Common side effects include mild, transient reactions such as nausea, vomiting, or a feeling of warmth. More serious, though less common, adverse reactions can include allergic-type responses, bronchospasm, and nephrotoxicity, especially in patients with pre-existing renal impairment.
3. Has iothalamate meglumine been superseded by newer contrast agents?
While newer generations of iodinated and non-iodinated contrast agents exist, iothalamate meglumine remains a widely used agent due to its established efficacy, availability, and cost-effectiveness, particularly in its generic forms. It is still considered a viable option for many diagnostic procedures.
4. What is the typical shelf life of iothalamate meglumine injections?
The shelf life of iothalamate meglumine injections is typically two to three years when stored under recommended conditions, protected from light and at controlled room temperature. Expiration dates are clearly indicated on product packaging.
5. How does the cost of iothalamate meglumine compare to other contrast agents?
Generic iothalamate meglumine is generally one of the more cost-effective iodinated contrast agents available, especially when compared to newer, more specialized contrast agents or gadolinium-based agents used in MRI. This cost advantage contributes to its continued use in healthcare systems with budget constraints.
Sources
[1] Grand View Research. (2023). Contrast Media Market Size, Share & Trends Analysis Report By Type (Iodinated, Gadolinium Based, Barium Based, Radioactive), By Application (CT, MRI, X-ray, Ultrasound), By End-use (Hospitals, Diagnostic Imaging Centers), By Region, And Segment Forecasts, 2023-2030.
[2] Mordor Intelligence. (2023). Computed Tomography (CT) Scanners Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023-2028).
[3] United Nations Department of Economic and Social Affairs, Population Division. (2022). World Population Prospects 2022.
[4] Allied Market Research. (2023). Contrast Media Market: Global Opportunity Analysis and Industry Forecast, 2023-2032.
[5] United States Pharmacopeia. (2023). Iothalamate Meglumine Injection.
[6] Food and Drug Administration. (2023). Guidance for Industry: ANDAs for Certain Highly Purified Antibiotic and Steroid Drug Products. (While this is a specific guidance, it illustrates the rigorous process for drug approval, applicable in principle to contrast agents.)
